Spotlight On... Novartis finds buyer to save 270 jobs at German plant; Sanofi, Google win EU nod for diabetes JV; Lupin eyes Japan growth; Pharma lines up against reviving pay-for-delay suit; and more...

Novartis ($NVS) was all set to close the door on a Sandoz intermediates plant in Germany last year, thanks to some hefty competition from Asia. But now, the Swiss pharma giant has a buyer willing to take the plant--and salvage the 270 jobs that would have been chopped. More from FiercePharmaManufacturing

@FiercePharma: Dana-Farber and MIT team says financial engineering could help pay for big-ticket meds. More | Follow @FiercePharma

> Sanofi ($SNY) won European approval for its diabetes-focused joint venture with Google's parent company Alphabet ($GOOG). Report

> India's Lupin plans to invest in Japan, with hopes of getting 20 drugs to market there in the coming quarters. Report

> In amicus briefs, two pharma industry groups urged the Third Circuit to affirm a lower court ruling that tossed out a pay-for-delay case against Pfizer's ($PFE) Wyeth unit and generics maker Teva ($TEVA). Report

> Pfizer asked a U.S. district judge to bar some expert testimony in pending lawsuits over alleged birth defects linked to its antidepressant Zoloft; Legal Intelligencer judged the litigation "on the verge of collapse." Report

Medical Device News

@FierceMedDev: Propeller partners with Aptar in hopes of winning race to first integrated 'smart' inhaler. Story | Follow @FierceMedDev

> Boston Scientific's Brazilian operations under investigation, as co-founder to depart. More

> J&J's LifeScan rolls out blood glucose meter with color-based results. News

Biotech News

@FierceBiotech: Blocked and tackled by the FDA, AcelRx spikes on upbeat update on PhIII pain study. Article | Follow @FierceBiotech

> Backed by Bill Gates, low-profile Exicure steps into spotlight with a $42M R&D gamble. Story

> Booming WuXi eyes $1.5B IPO for biologics unit: report. More

CRO News

> A year after its LabCorp buyout, Covance posts steady sales. More

> WuXi's reportedly spinning off its biologics biz in an IPO. Report

> Post-Pfizer Icagen pairs up with Aptuit for drug discovery. Story

> Deal-hungry Icon posts solid final quarter results. Article

Pharma Manufacturing News

> Indian quality moves underway as industry, regulators meet. Report

> Indian pharma snaps up U.S. manufacturing with $1.5B worth of deals in 2015. More

> Japan's Mitsubishi Tanabe expected to have fast-production flu vaccine ready by 2019. Item

> Seqirus adding vax production facility in U.K. Story

> ICIG acquiring Novartis intermediates plant that was set to fold. Article

Pharma Asia News

> Japan's Otsuka announces new plan for delamanid to help curb TB. News

> India kicks off 'red line' guide on antibiotic overprescription. More

> Hong Kong seeks a seat at precision medicine services table. Report

> Indian drug firms bought big in 2015 M&A with U.S. manufacturing focus. Story

> Drug manufacturing quality standards push on in India. Article

And Finally... What happens when cancer patients have to deal with other physical problems? Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.